The Stress Response Mediator ATF3 Represses Androgen Signaling by Binding the Androgen Receptor

REFERENCES

• Adachi M, et al. 2000. Androgen-insensitivity syndrome as a possible coactivator disease. N. Engl. J. Med. 343:856–862.
   PubMed Web of Science ®Google Scholar
• Andersen R, et al. 2010. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:535–546.
   PubMed Web of Science ®Google Scholar
• Beleza-Meireles A, et al. 2008. Activating transcription 3: a hormone responsive gene in the etiology of hypospadias. Eur. J. Endocrinol. 158:729–739.
   PubMed Web of Science ®Google Scholar
• Best CJM, et al. 2005. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin. Cancer Res. 11:6823–6834.
   PubMed Web of Science ®Google Scholar
• Brinkmann AO. 2001. Molecular basis of androgen insensitivity. Mol. Cell Endocrinol. 179:105–109.
   PubMed Web of Science ®Google Scholar
• Cai C, et al. 2011. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20:457–471.
   PubMed Web of Science ®Google Scholar
• Carson-Jurica MA, Schrader WT, O'Malley BW. 1990. Steroid receptor family: structure and functions. Endocr. Rev. 11:201–220.
   PubMed Web of Science ®Google Scholar
• Centenera MM, Harris JM, Tilley WD, Butler LM. 2008. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol. Endocrinol. 22:2373–2382.
   PubMed Web of Science ®Google Scholar
• Chen BPC, Liang G, Whelan J, Hai T. 1994. ATF3 and ATF3ΔZip: transcriptional repression versus activation by alternatively spliced isoforms. J. Biol. Chem. 269:15819–15826.
   PubMed Web of Science ®Google Scholar
• Chen SY, et al. 2006. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer proliferation. Oncogene 25:7212–7223.
   PubMedGoogle Scholar
• Gao N, et al. 2003. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcripitonal regulation of prostatic genes. Mol. Endocrinol. 17:1484–1507.
   PubMedGoogle Scholar
• Gilchrist M, et al. 2006. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441:173–178.
   PubMed Web of Science ®Google Scholar
• Hai T, Hartman MG. 2001. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273:1–11.
   PubMed Web of Science ®Google Scholar
• Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U. 1999. ATF3 and stress responses. Gene Expr. 7:321–325.
   PubMed Web of Science ®Google Scholar
• Hai T, Wolford CC, Chang Y-S. 2010. ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Exp. 15:1–11.
   PubMed Web of Science ®Google Scholar
• Hartman MG, et al. 2004. Role for activating transcription factor 3 in stress-induced β-cell apoptosis. Mol. Cell. Biol. 24:5721–5732.
   PubMed Web of Science ®Google Scholar
• He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. 1999. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain. J. Biol. Chem. 274:37219–37225.
   PubMed Web of Science ®Google Scholar
• He B, Kemppainen JA, Wilson EM. 2000. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275:22986–22994.
   PubMed Web of Science ®Google Scholar
• He B, Lee LW, Minges JT, Wilson EM. 2002. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J. Biol. Chem. 277:25631–25639.
   PubMed Web of Science ®Google Scholar
• Heemers HV, Tindall DJ. 2005. Androgen receptor coregulatory proteins as potential therapeutic targets in the treatments of prostate cancer. Curr. Cancer Ther. Rev. 1:175–186.
   Google Scholar
• Heemers HW, Tindall DJ. 2008. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28:778–808.
   Google Scholar
• Jiang H-Y, et al. 2004. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol. Cell. Biol. 24:1365–1377.
   PubMed Web of Science ®Google Scholar
• Jorgensen JS, Nilson JH. 2001. AR suppresses transcription of the α glycoprotein hormone subunit gene through protein-protein interactions with cJun and activating transcription factor 2. Mol. Endocrinol. 15:1496–1504.
   PubMedGoogle Scholar
• Kalfa N, Philibert P, Sultan C. 2008. Is hypospadias a genetic, endocrine or environmental disease, or still an unexplained malformation? Int. J. Androl. 32:187–197.
   PubMedGoogle Scholar
• Kang Y, Chen C, Massague J. 2003. A self-enabling TGFß response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial Cells. Mol. Cell 11:915–926.
   PubMedGoogle Scholar
• Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K. 2010. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol. Cancer Ther. 9:3175–3185.
   PubMed Web of Science ®Google Scholar
• Kourtis N, Tavernarakis N. 2011. Cellular stress response pathways and ageing: intricate molecular relationships. EMBO J. 30:2520–2531.
   PubMed Web of Science ®Google Scholar
• Lamont KR, Tindall DJ. 2010. Androgen regulation of gene expression. Adv. Cancer Res. 107:137–162.
   PubMedGoogle Scholar
• Landschulz WH, Johnson PF, McKnight SL. 1988. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 240:1759–1764.
   PubMed Web of Science ®Google Scholar
• Langley E, Kemppainen JA, Wilson EM. 1998. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J. Biol. Chem. 273:92–101.
   PubMed Web of Science ®Google Scholar
• Lapointe J, et al. 2004. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 101:811–816.
   PubMed Web of Science ®Google Scholar
• Li J, Fu J, Toumazou C, Yoon H-G, Wong J. 2006. A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol. Endocrinol. 20:776–785.
   PubMed Web of Science ®Google Scholar
• Liao G, et al. 2003. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 278:5052–5061.
   PubMed Web of Science ®Google Scholar
• Lin C, et al. 2009. Nuclear receptor-induced chromosomal proximity and DNA breaks underlies specific translocations in cancer. Cell 139:1069–1083.
   PubMed Web of Science ®Google Scholar
• Lin D-Y, et al. 2004. Negative regulation of androgen receptor transcriptional activity by Daxx. Mol. Cell. Biol. 24:10529–10541.
   PubMedGoogle Scholar
• Liu G-Z, Wang H, Wang Z. 2003. Identification of a highly conserved domain in the androgen receptor that suppresses the DNA-binding domain-DNA interactions. J. Biol. Chem. 278:14956–14960.
   PubMedGoogle Scholar
• Liu W, et al. 2011. KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFκB complex in human prostate cancer. J. Biol. Chem. 286:18949–18959.
   PubMedGoogle Scholar
• Mani R-S, et al. 2009. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326:1230.
   PubMed Web of Science ®Google Scholar
• Mantoni TS, Reid G, Garrett MD. 2006. Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. Oncogene 25:3139–3149.
   PubMedGoogle Scholar
• Massie CE, et al. 2007. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 8:871–878.
   PubMed Web of Science ®Google Scholar
• Mo P, Wang H, Lu H, Boyd DD, Yan C. 2010. MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J. Biol. Chem. 285:26908–26915.
   PubMedGoogle Scholar
• Ni L, Yang C-S, Gioeli D, Frierson H, Toft DO, Paschal BM. 2010. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol. Cell. Biol. 30:1243–1253.
   PubMedGoogle Scholar
• Norris J, et al. 2009. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell 36:405–416.
   PubMedGoogle Scholar
• Pan Y, Chen H, Siu F, Kilberg MS. 2003. Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter. J. Biol. Chem. 278:38402–38412.
   PubMedGoogle Scholar
• Pelzer AE, et al. 2006. The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J. Urol. 175:1517–1522.
   PubMedGoogle Scholar
• Phizicky E, Fields S. 1995. Protein-protein interactions: Methods for detection and analysis. Microbiol. Rev. 59:94–123.
   PubMedGoogle Scholar
• Qi W, Wu H, Yang L, Boyd DD, Wang Z. 2007. A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression. EMBO J. 26:65–75.
   PubMedGoogle Scholar
• Quigley CA, et al. 1995. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16:271–321.
   PubMed Web of Science ®Google Scholar
• Sato N, et al. 1997. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J. Biol. Chem. 272:17485–17494.
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. 2005. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23:8253–8261.
   PubMed Web of Science ®Google Scholar
• Shen M, Abate-Shen C. 2010. Molecular genetics of prostate cancer: new prospects for old challenges. Gene Dev. 24:1967–2000.
   PubMed Web of Science ®Google Scholar
• Shenk J, et al. 2001. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J. Biol. Chem. 276:38472–38479.
   PubMedGoogle Scholar
• Stanbrough M, Leav I, Kwan PL, Bubley GJ, Balk SP. 2001. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 98:10823–10828.
   PubMed Web of Science ®Google Scholar
• Tam NN, Gao Y, Leung YK, Ho SM. 2003. Androgenic regulation of oxidative stress in the rat prostate: Involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am. J. Pathol. 163:2513–2522.
   PubMed Web of Science ®Google Scholar
• Taylor B, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11–22.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, et al. 2007. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39:41–51.
   PubMed Web of Science ®Google Scholar
• Vander Griend DJ, et al. 2009. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol. Cancer Ther. 8:1340–1349.
   PubMed Web of Science ®Google Scholar
• Wang C, et al. 2003. Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen. J. Biol. Chem. 278:32423–32430.
   PubMedGoogle Scholar
• Wang H, Mo P, Ren S, Yan C. 2010. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. J. Biol. Chem. 285:13201–13210.
   PubMedGoogle Scholar
• Wang L, Hsu C-L, Chang C. 2005. Androgen receptor corepressors: an overview. Prostate 63:117–130.
   PubMed Web of Science ®Google Scholar
• Wang Q, et al. 2009. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245–256.
   PubMed Web of Science ®Google Scholar
• Weatherman RV, Fletterick RJ, Scanlan TS. 1999. Nuclear-receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 68:559–581.
   PubMed Web of Science ®Google Scholar
• Yan C, Boyd DD. 2006. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Mol. Cell. Biol. 26:6357–6371.
   PubMedGoogle Scholar
• Yan C, Lu D, Hai T, Boyd DD. 2005. Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J. 24:2425–2435.
   PubMed Web of Science ®Google Scholar
• Yan C, Wang H, Boyd DD. 2001. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-κB binding to the promoter as a consequence of IκBα-induced block of p65/p50 nuclear translocation. J. Biol. Chem. 276:1164–1172.
   PubMed Web of Science ®Google Scholar
• Yin X, Dewille JW, Hai T. 2008. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27:2118–2127.
   PubMed Web of Science ®Google Scholar
• Zhang J, Thomas TZ, Kasper S, Matusik RJ. 2000. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698–4710.
   PubMed Web of Science ®Google Scholar